Code | Description |
---|---|
A9606 | Radium ra-223 dichloride, therapeutic, per microcurie |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 10 | 28 | 6 | 2 | 23 | 65 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 2 | — | 1 | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Castration-resistant prostatic neoplasms | D064129 | — | — | 10 | 9 | 2 | — | 17 | 33 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Adenocarcinoma | D000230 | — | — | 2 | 3 | — | — | 1 | 5 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 5 | — | — | — | 5 |
Bone neoplasms | D001859 | EFO_0003820 | D16 | 1 | 2 | — | — | 1 | 4 |
Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | 1 | 3 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | 2 | — | — | — | 3 |
Multiple myeloma | D009101 | — | C90.0 | 2 | 2 | — | — | — | 2 |
Triple negative breast neoplasms | D064726 | — | — | — | 1 | — | — | — | 1 |
Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 1 | — | — | — | 1 |
Small cell lung carcinoma | D055752 | — | — | — | 1 | — | — | — | 1 |
Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Urologic neoplasms | D014571 | — | C64-C68 | 1 | — | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Bone diseases | D001847 | — | M89.9 | 1 | — | — | — | — | 1 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Radium ra-223 |
INN | — |
Description | Radium-223 (223Ra, Ra-223) is an isotope of radium with an 11.4-day half-life. It was discovered in 1905 by T. Godlewski, a Polish chemist from Kraków, and was historically known as actinium X (AcX). Radium-223 dichloride is an alpha particle-emitting radiotherapy drug that mimics calcium and forms complexes with hydroxyapatite at areas of increased bone turnover. The principal use of radium-223, as a radiopharmaceutical to treat metastatic cancers in bone, takes advantage of its chemical similarity to calcium, and the short range of the alpha radiation it emits.
|
Classification | Small molecule |
Drug class | quaternary ammonium derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | [223Ra] |
PDB | — |
CAS-ID | 15623-45-7 |
RxCUI | — |
ChEMBL ID | CHEMBL4297420 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | — |